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We have discovered that human 
endothelial cells undergo two forms of 
cell death. 
1. A non-specific form of cell death, 
similar to that of other normal and 
neoplastic cells 
2. A unique form of cell death, seen 
only in endothelial cells, associated 
with massive accumulation of 
calcium. We call this massive 
calcium accumulation death, or 
MCAD. 
3. MCAD may be identified by 
cytochemical staining with:
a. Fast Green/Hematoxylin
b. Fast Green/Wright-Giemsa, or
c. Alizarin red S (most adevantageous)
In the presence of Fast Green/
Hematoxylin, calcium is identified 
by a blue-black “lake” staining 
Human Umbilical Vein Endothelial Cells
ImageJ Color (RGB) image quantification
In the presence of Alizarin red 
S, calcium is identified by an 
orange-red “lake” staining 
Bähr et al reported that 22 of 36 glioblastoma patients treated with 
bevacizumab showed tumor calcifications on 8 week post therapy follow up 
with MRI. Early tumor calcification strongly predicted for response, time to 
progression, and overall survival (Neuro-Oncology, 13:1020, 2011, doi:
10.1093/neuonc/nor099). The authors didnʼt understand the mechanism, but 
speculated that it was vascular in nature. At the 13th International Anti-
Angiogenic Symposium (2011), we presented our discovery of the 
phenomenon of massive calcium accumulation death, wherein MCAD occurred 
in endothelial cells (tumor, circulating, and HUVEC), in response to VEGF 
depletion by bevacizumab and other putative anti-angiogenic agents, but not in 
response to non-specific cytotoxins http://precedings.nature.com/documents/
6647/version/1 , J Intern Med, In Press.  In subsequent work, we have 
documented marked MCAD to occur in primary microcluster cultures from 6 
fresh human glioblastoma biopsies, following 96 hours of VEGF depletion in 
vitro by bevacizumab (see examples below).  The presence and degree of 
MCAD is strikingly dependent on the type of serum in the culture medium 
(RPMI-1640 + 25% serum) -- typically most striking in (very low VEGF) fetal 
calf serum, but inhibited (often) or enhanced (rarely) by 25% human serum 
from different patients or normal donors containing variable quantities of VEGF. 
There was not a linear relationship between VEGF concentration and MCAD 
inhibition (or enhancement), suggesting that other pro-angiogenic (or anti-
angiogenic) serum factors may play a role. In epithelial metastatic tumors, 
circulating peripheral blood endothelial cells may be easily tested, using our 
methods, and the serum inhibition (or, rarely, enhancement) is faithfully 
reproduced on circulating endothelial cells, in comparison with the tumor 
cluster-associated endothelial cells. We propose MCAD as the mechanism of 
glioblastoma calcification following bevacizumab and further propose that 
testing tumor microclusters and/or circulating endothelial cells, in the presence 
of autologous serum, could be a useful predictive biomarker and research tool.
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Conclusions: Bevacizumab 
induces massive calcium 
accumulation death in 
endothelial cells in situ in 
tumor microcluster culture and 
in circulating endothelial cells. 
Bevacizumab resistance is a 
function of both intrinsic 
susceptibility to VEGF 
depletion and to the apparent 
presence of angiogenic 
modulators (other than VEGF) 
circulating in human serum.
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